In vitro activities of new and conventional antimycotics against fluconazole‐susceptible and non‐susceptible Brazilian Candida spp. isolates

Abstract

The substantial increase in the rate of azole resistant Candida spp. yeast infections has become a serious treatment problem requiring new and more active antifungal agents. In this study, the in vitro activities of ravuconazole and albaconazole were compared with those of amphotericin B, flucytosine, itraconazole and fluconazole against 162 Brazilian isolates of Candida spp. from which 48 isolates had previously shown lower susceptibility or resistance to fluconazole. Ravuconazole susceptibility ranged from 84.6% (Candida albicans) to 100% for other species and albaconazole MIC(90) was < or =1.0 microg ml(-1) for all the species emphasising the potent activity of these triazoles. To our knowledge this is the first study evaluating the susceptibility of C. dubliniensis to albaconazole.

Synthetic arylquinuclidine derivatives exhibit antifungal activity against Candida albicans, Candida tropicalis and Candida parapsilopsis

“…Examples of recent approaches to antifungal treatments include new triazoles such as ravuconazole and albaconazole, which display a broad-spectrum activity against yeast and filamentous fungi, including species resistant to fluconazole and itraconazole [22]. In addition, the use of inhibitors from other steps of sterol biosynthesis is an alternative approach to the development of new chemotherapeutic agents.…”

In vitro antifungal susceptibility of Candida spp. oral isolates from HIV-positive patients and control individuals

“…Alves et al 27 found that among isolates susceptible to fluconazole, the activity of flucytosine was highest against C. albicans (84.6%) and C. glabrata (94.1%). Additionally, they reported that 40% of C. krusei isolates were susceptible to flucytosine.…”

“…Additionally, they reported that 40% of C. krusei isolates were susceptible to flucytosine. Alves et al 27 have argued that the great potential of flucytosine against C. glabrata has not been sufficiently explored and that this antifungal may be used as a treatment option when resistance to azoles is observed. In our study, the C. glabrata isolate was susceptible to fluconazole and flucytosine.…”

QSAR studies of a number of triazole antifungal alcohols

“…The substance with the highest in vitro activity is compound 20, which was supported by results investigations, reported between 2000 and 2008. A recent name of compound 20 is Albaconazol (UR-9825) [53][54][55][56] and it is undergoing Phase II clinical trials, but its future is uncertain. Further investigation is needed in order to gain insight into the precise relationships linking chemical structure and pharmacological activity for fungicide substances in vivo.…”